- * Treatment with prothrombin complex concentrates (PCCs) other than Beriplex® P/N
- * Acquired deficiency of the vitamin K-dependent coagulation factors (e.g., as induced by treatment with oral vitamin K antagonists)
Coagulation Protein Disorders
Observational Study of Prophylaxis and Treatment of Acute Perioperative Bleeding With Beriplex® P/N (Probe Study)
NCT01053169 | OBSERVATIONAL
Beriplex® P/N is made from human plasma (the liquid part of the blood) and contains the coagulation factors II, VII, IX and X which are important for blood clotting (coagulation). Lack of any of these factors means that blood does not clot as quickly as it should and so there is an increased tendency to bleed. This observational study was designed to evaluate the effectiveness of Beriplex® P/N in the prevention (prophylaxis) and treatment of bleeding during surgery (perioperative bleeding) in a routine clinical setting.
Trial Information
If interested, contact clinicaltrials@cslbehring.com or +1 610-878-4697 for more information
CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy
Royal Blackburn Hospital
Blackburn,United Kingdom
Blackpool
Blackpool,United Kingdom,FY38NR
Addenbrokes
Cambridge,United Kingdom,CB233RE
Royal Free Hospital
London,United Kingdom,CB233RE
Derriford Hospital
Plymouth,United Kingdom,CB233RE
Southhampton General Hospital
Southhampton,United Kingdom,CB233RE
Study Eligibility Criteria
Additional Studies
Additional studies can be found at ClinicalTrials.gov